T-Lymphoblastic Leukemia / Lymphoma · line 1 · Hyper-CVAD + Rituximab (CD20+) — alternating courses A/B, 8 cycles total

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-HYPER-CVAD-R`

ID	`IND-T-ALL-1L-HYPER-CVAD`
Type	Indication
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-T-ALL`
Sources	`SRC-NCCN-BCELL-2025`

Notes

STUB. CD19/CD22 CAR-T NOT applicable (T-cell). Nelarabine — T-cell selective, R/R standard.

Used By

Algorithms

ALGO-T-ALL-1L - ALGO-T-ALL-1L